NCT07042100View on ClinicalTrials.gov

A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.

PHASE1RecruitingINTERVENTIONAL
Enrollment

177

Participants

Timeline

Start Date

July 17, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2030

Conditions
Advanced Solid Tumors
Interventions
BIOLOGICAL

Dose level (DL)1

Administered IV every 3 weeks

BIOLOGICAL

DL2

Administered IV every 3 weeks

BIOLOGICAL

DL3

Administered IV every 3 weeks

BIOLOGICAL

DL4

Administered IV every 3 weeks

BIOLOGICAL

DL5

Administered IV every 3 weeks

Trial Locations (4)

4557

RECRUITING

SPARC Investigative Site, Birtinya

77030

RECRUITING

SPARC Investigative Site, Houston

110029

NOT_YET_RECRUITING

SPARC Investigative Site, Delhi

400012

NOT_YET_RECRUITING

SPARC Investigative Site, Mumbai

All Listed Sponsors
lead

Sun Pharma Advanced Research Company Limited

INDUSTRY